Technology ID
E-125-2018-1

Reducing Bloodstream Neutrophils as a Treatment for Lung Infection and Inflammation

Linked ID
TAB-3436
Inventors
Carmen Williams (NIEHS)
Michael Fessler (NIEHS)
Wan-Chi Lin (NIEHS)
Lead Inventors
Michael Fessler (NIEHS)
Co-Inventors
Carmen Williams (NIEHS)
Wan-Chi Lin (NIEHS)
Development Stages
Pre-clinical (in vivo)
ICs
NIEHS
Commercial Applications
An EMP2 inhibitor can be developed for the treatment or prophylaxis for a wide variety of neutrophil-dependent lung disorders, such as:.

  • acute lung injury
  • pneumonia (bacterial, viral, fungal)
  • bronchiectasis
  • COPD and asthma
  • radiation- or chemotherapeutic-induced pneumonitis
  • idiopathic or induced interstitial lung disease
  • bronchopulmonary dysplasia
  • lung transplant rejection
Competitive Advantages
  • EMP2 can selectively target PMN accumulation in the lung, rather than broadly affecting PMN trafficking through all tissues

Request More Info

Licensing Contact